NCT03378414View on ClinicalTrials.gov

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 6
Interventions
PROCEDURE

Intravenous infusion

Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)

PROCEDURE

Intrathecal injection

Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)

BIOLOGICAL

umbilical cord mesenchymal stem cell

Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure

All Listed Sponsors
lead

Sclnow Biotechnology Co., Ltd.

INDUSTRY